Back to top
more

AMN Healthcare Services (AMN)

(Real Time Quote from BATS)

$42.92 USD

42.92
156,852

+0.29 (0.68%)

Updated Sep 27, 2024 11:30 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (164 out of 251)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Avantor, Inc. (AVTR) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Avantor, Inc. (AVTR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Quest Diagnostics (DGX) Q2 Earnings Beat, Base Testing Strong

by Zacks Equity Research

According to Quest Diagnostics (DGX), Q2 is the first quarter since 2019 in which it has registered organic base testing revenue growth.

Is AMN Healthcare Services (AMN) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (AMN) Outperforming Other Medical Stocks This Year?

Abbott (ABT) Q2 Earnings Beat, Molecular Diagnostic Sales Drop

by Zacks Equity Research

Abbott's (ABT) Adult Nutrition sales benefit from improved sales performance of complete and balanced nutrition brand Ensure and diabetes nutrition brand, Glucerna in Q2.

AMN Healthcare (AMN) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

AMN Healthcare (AMN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Nevro's (NVRO) Senza System Approved by FDA for PDN Treatment

by Zacks Equity Research

Nevro's (NVRO) 10 kHz SCS treatment, which has received the FDA nod for treating patients with PDN, is expected to provide sustained pain relief as well as improve health-related quality of life.

    Nevro (NVRO) Reports Impressive Preliminary Q2 Revenues

    by Zacks Equity Research

    Improvement in Nevro's (NVRO) second-quarter revenues is likely to have resulted from a solid product portfolio.

    Neogen (NEOG) Misses Q4 Earnings, Tops Revenue Estimates

    by Zacks Equity Research

    Strong segmental revenues and solid international performance across Neogen's (NEOG) entire business drove its topline.

    Intuitive Surgical (ISRG) Q2 Earnings & Revenues Top Estimates

    by Zacks Equity Research

    Intuitive Surgical's (ISRG) second-quarter results reflect strong segmental performance.

    Masimo (MASI) Boosts Its Product Suite With Latest Release

    by Zacks Equity Research

    Masimo's (MASI) latest offering is expected to improve patient care due to its re-engineered integration design.

    Here is Why Growth Investors Should Buy AMN Healthcare (AMN) Now

    by Zacks Equity Research

    AMN Healthcare (AMN) is well positioned to outperform the market, as it exhibits above-average growth in financials.

    Reasons to Add Veeva Systems (VEEV) Stock to Your Portfolio

    by Zacks Equity Research

    Investors continue to be optimistic about Veeva Systems (VEEV) on its slew of partnerships and robust product adoptions.

    Catalent (CTLT) Inks Deal for Feasibility Study of CBD Product

    by Zacks Equity Research

    Catalent's (CTLT) latest agreement is expected to lead to a prototype development of a Zydis formulation via a feasibility study.

    3 Reasons to Add LHC Group (LHCG) Stock to Your Portfolio

    by Zacks Equity Research

    Investors continue to be optimistic about LHC Group (LHCG) owing to its slew of deals and a broad array of services.

    AngioDynamics (ANGO) Q4 Earnings Match Estimates, Revenues Top

    by Zacks Equity Research

    AngioDynamics (ANGO) registers strong revenue growth across all its GBUs in fiscal 2021 Q4.

    Amedisys (AMED) Latest New York Assets Buyout Aids Home Health

    by Zacks Equity Research

    The latest development remains in line with Amedisys' (AMED) ongoing efforts to expand footprint in key markets.

    Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

    by Zacks Equity Research

    Sector ETF report for PSCH

    Inogen (INGN) Hits New 52-Week High: What's Driving It?

    by Zacks Equity Research

    Investors are optimistic about Inogen's (INGN) direct-to-customer business model and a strong product portfolio.

    Charles River (CRL) at a 52-Week High: What's Driving It?

    by Zacks Equity Research

    Strong performance by the RMS, DSA and Manufacturing segments is driving the top line for Charles River (CRL).

    This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar

    by Zacks Equity Research

    The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.

    BD's (BDX) Digital Marketplace Set to Improve User Experience

    by Zacks Equity Research

    BD's (BDX) latest online marketplace is expected to offer a better user experience to its flow cytometry users.

    LHC Group (LHCG) & SCP Health to Offer Home Health Services

    by Zacks Equity Research

    LHC Group (LHCG) collaborates with SCP Health to provide innovative and advanced in-home healthcare services.

    Intuitive Surgical (ISRG) Hits 52-Week High: What's Behind It?

    by Zacks Equity Research

    Investors are optimistic about Intuitive Surgical's (ISRG) strength in its da Vinci surgical system.

    West Pharmaceutical (WST) Hits 52-Week High: What's Driving It?

    by Zacks Equity Research

    Investors are optimistic about West Pharmaceutical's (WST) solid proprietary products segment.

    Bowen Center Expands Access to Care via NextGen's (NXGN) Platform

    by Zacks Equity Research

    NextGen's (NXGN) platform is likely to expand care to the underserved patient pool by improving the access to and delivery of whole-person care.